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Introduction 25
Prostaglandin D 2 (PGD 2 ), secreted during mast cell activation (Dahlen and Kumlin, 2004) , 26 and its metabolite 9-11 PGF 2 are used as a non-invasive biomarkers in patients with 27 asthma (O' Sullivan et al., 1996) . PGD 2 is part of the acute asthmatic airway response; levels 28 of this mediator can be found within minutes in BAL fluid and at 150-fold higher biologically 29 active levels than before the exacerbation (Liu et al., 1991) . In addition to the acute reaction, 30 PGD 2 has through recruitment of inflammatory cells been suggested to contribute to the 31 formation of the chronic asthmatic inflammation and subsequent airway remodelling (Balzar 32 et al., 2011). 33 34 PGD 2 , generated from arachidonic acid, is converted to PG via cyclooxygenase (COX) (Vane, 35 1971 ) and PGD synthase (Urade and Eguchi, 2002) . There are two distinct types of PGDS; 36
hematopoietic (H-PGDS) and lipocalin-type (L-PGDS). H-PGDS is highly expressed in mast 37
cells, eosinophils, macrophages, and lymphocytes as well as structural cells such as epithelial 38 cells and fibroblasts, whereas L-PGDS is mainly expressed in the central nervous system and 39 heart (Okano et al., 2006) . PGD 2 exits the cell via a carrier-mediated process and activates 40 specific G-protein coupled receptors on target cells. PGD 2 is classified to mediate its effect via 41 the DP 1 (Coleman et al., 1994) PGD 2 induced concentration-dependent contractions in the lung parenchyma (Fig. 1A and B) . 156
The contraction (79.8 ± 8.5%), obtained at the highest concentration used (100 µM), was 157 according to the non-linear regression analysis not the maximal effect. The inability of PGD 2 158 to reach the maximum capacity of the tissue contrasted to U46619 (Fig. 1C and D) , which 159 induced a contraction reaching similar or higher maximum effect as the high concentrations 160 of histamine, acetylcholine and potassium chloride used as the reference at the end of each 161 experiment (108 ± 4.6%) and with a 30-fold greater potency than PGD 2 (pEC 50 : 6.68 ± 0.24 162 and 5.14 ± 0.22, repectively). However, the concentration-response curves for both PGD 2 and 163 U44619 were markedly shallow with Hill slopes significantly below 1 (0.58 ± 0.04 and 0.53 ± 164 0.05) . 165
166
When preparations were treated with the competitive TP receptor antagonist SQ-29548, the 167 concentration-response curve to PGD 2 was shifted to the right (Fig. 1A) . Pretreatment with 168 0.1 or 1 µM of SQ-29548 gave rise to significantly different pEC 50 values (4.7 ± 0.1 and 4.2 ± 169 0.1, respectively) compared to control (5.4 ± 0.3; table 1). At these concentrations of SQ-170 29548, the Hill slope was significantly higher than for the control. Further experiments with 171 the combined TP and DP 2 receptor antagonist BAYu3405 (Fig. 1B) respectively), compared to control (7.2 ± 0.4; Fig. 1D ). To quantify the antagonistic capacity 182 for SQ-29548 and BAYu3405, Schild plot analysis was performed, assuming that the agonist 183 curves reached the similar maximum and ignoring the absence of parallel shifts. Although the 184 antagonists showed a linear regression statistically not deviating from unity it was a tendency 185 for lower Schild slopes for both SQ-29548 (0.89 ± 0.08 for PGD 2 ; P = 0.250; and 0.85 ± 0.18 186 for U46619; P = 0.521) and BAYu3405 (0.71 ± 0.25 for PGD 2 ; P = 0.375; and 0.84 ± 0.13 for 187 U46619; P = 0.364). The pK B values for the experiments with SQ-2954 rendered a 10-fold 188 differences between PGD 2 and U46619 (7.14 ± 0.08 and 8.17 ± 0.18, respectively) whereas 189 no significant difference was seen in the experiments with BAYu3405 (7.82 ± 0.15 and 7.60 ± 190 0.16 for PGD 2 and U46619, respectively). 191
192
To test if the difference between PGD 2 and U46619 could relate to metabolism of PGD 2 , into 193 a compound activating other receptors, the early PGD 2 metabolite 9α,11β-PGF 2 was studied. 194 9α,11β-PGF 2 yielded a weaker response than both U46619 and PGD 2 , reaching only about 30 195 % of the maximum contraction ( 
The DP 1 receptor induce a weak relaxation of peripheral lung tissue 205
The DP 1 receptor has been described to mediate relaxation of vascular and bronchial SMCs 206 (Norel, 2007) . Therefore, it was investigated if the DP 1 receptor may mediate relaxation of 207 peripheral lung tissue. Lung strips were treated with cumulative concentrations of the DP 1 208 receptor agonist BW245C after pre-contraction with 10 nM of LTD 4 . The pre-contracted 209 strips relaxed at the highest concentration of BW245C (10 µM) (Fig 3A) . Based on these 210 results, experiments with the DP 1 receptor antagonist BWA868C (0.1 and 1 µM) were 211 performed with the hypothesis that inhibition of the DP 1 receptor should enhance the PGD 2 212 induced contractions. However, the BWA868C treated preparations yielded pEC 50 values for 213 PGD 2 that were not significant different from controls (Fig. 3B and table 2) . 214 215
The DP 2 receptor induce neither contraction nor relaxation 216
Since BAYu3405 is both a TP and DP 2 receptor antagonist, the DP 2 receptor mediated 217 response in the parenchyma was investigated. Cumulative concentrations of the DP 2 receptor 218 agonist DK-PGD 2 were added to the lung preparations both before and after pre-contraction 219 with LTD 4 . DK-PGD 2 up to 10 µM generated neither significant contraction nor relaxation of 220 the peripheral lung tissue (n=5, data not shown). 221 222
The effects of PGD 2 and U46619 in airways and pulmonary vessels in precision-cut lung 223 slices 224
Since the lung parenchyma preparation consists of both airways and vessels, precision cut 225 lung slices were examined to study the contractile effect of PGD 2 and U46619 in peripheral 226 airways and pulmonary arteries and veins. Indeed, PGD 2 induced contractile effects in 227 airways (pEC 50 : 6.8 ± 0.1) as well as both pulmonary veins (pEC 50 : 7.2 ± 0.2) and arteries 228 (pEC 50 : 6.0 ± 0.2; Fig. 4A ). U46619 induced similar strong contractile responses but was 229 significantly more potent in airways (pEC50: 8.9 ± 0.2), veins (pEC 50 : 9.2 ± 0.2) and arteries 230 (pEC 50 : 8.1± 0.2) in the lung parenchymal preparation (Fig. 4B) . 231 232
Role of prostanoids on antigen-induced contractions 233
Since the contractile effect of both PGD 2 and U46619 was mediated through the TP receptor, 234 experiments with SQ-29548 were performed to study the significance of this receptor in the 235 early allergic reaction. Thus, cumulative challenge with ovalbumin on parenchymal strips 236 from sensitized guinea pigs caused a concentration-dependent contraction that reached about 237 60-70% of the maximum contraction. Pre-treatment with SQ-29548 partly decreased the 238 ovalbumin-induced contraction (P < 0.01). Analysis of the bath fluid after challenge with 239 ovalbumin (1 µg/mL) showed that TXB 2 (1021 ± 325 fmol/g; n=6) was released in 20-fold 240 higher concentration than PGD 2 (53 ± 6 fmol/g; n=6). Synthesis before ovalbumin stimulation 241 was 61 ± 51 fmol/g for TXB 2 and not detectable for PGD 2 . 
Discussion 254
It was found that the predominant effect of PGD 2 in the peripheral lung is a contractile effect 255 which is mediated through activation of TP receptors situated on airways as well as arteries 256 and veins in the parenchymal lung tissue. A minor relaxant effect was found to be mediated 257 through the DP 1 receptor and no effect was found to be mediated through the DP 2 in the 258 present study. When inducing ovalbumin activation of sensitized parenchymal strips, both 259 experiments can be due to activation of DP 2 receptors. However, as described in this study, a 295 negligible effect is shown when this receptor is selectively activated. Thus, from these 296 experiments the reason for the difference of the pK B values for SQ-29548 cannot be 297 completely concluded. Taking all these complexities of the actions of the agonists both in 298 absence and presence of antagonism in consideration, the clear antagonism with both these 299 known TP receptor antagonists indicates that the main action of PGD 2 goes through the TP 300 receptor. 301
The major PGD 2 metabolite, 9α,11β-PGF 2 , induced a weak contraction of the peripheral lung 303 that was blocked by SQ-29548 indicating that the breakdown of PGD 2 in this assay do not 304 cause activation of any further receptor then PGD 2 by itself. PGF 2α is a stereoisomer to 305 9α,11β-PGF 2 and closely structurally related to PGD 2 (Sandig et al., 2006) . Thus, one 306 possibility was that PGD 2 also acted through FP receptors (Kiriyama et al., 1997). Since there 307 are no specific receptor antagonists available for the FP receptor we chose to investigate how 308 the response to PGF 2α could be blocked by SQ-29548. However, as the effect of PGF 2α was 309 abolished by SQ-29548 it is unlikely that PGD 2 mediate any major effect through the FP 310 receptor. Altogether, these data implicate that PGF 2α , which along with PGD 2 has been shown 311 The present study highlights that the parenchymal constriction induced by PGD 2 should be 366 attributed to its properties as a TP receptor agonist. Even though PGD 2 may have minor role 367 as an agonist in the allergen-induced contraction in guinea pigs, since it is both released in 368 lower amount and have lesser effect than TXA 2 , the role in human may be of great importance 369 due to the high amount of mast cell release (Mita et al., 1999) . Accordingly, the contractile 370 effect of PGD 2 in human airways has also been shown to be antagonized by BAY u3405 371 Calculations for Emax, pEC 50 and Hill slope are presented as mean ± S.E.M.. 
